DSHEA Act Explained: How Supplements Are Regulated
The Dietary Supplement Health and Education Act (DSHEA) of 1994 established the regulatory framework for dietary supplements in the United States, distinguishing them from drugs and defining safety, labeling, and marketing requirements.
By dietarysupplement.ai·Article
The Dietary Supplement Health and Education Act (DSHEA), enacted in 1994, fundamentally shaped how dietary supplements are regulated in the United States. Unlike pharmaceuticals, which must prove safety and efficacy before reaching consumers, supplements operate under a different framework that prioritizes market access while establishing manufacturer responsibility for quality and truthful labeling. Understanding DSHEA is essential for anyone choosing supplements, as it defines what claims can be made, what safety standards apply, and how the FDA monitors the marketplace.
What Is DSHEA and Why Was It Created
Before 1994, the regulatory status of dietary supplements was ambiguous. The FDA treated most supplements as either food or drugs, applying inconsistent standards. Consumer demand for broader access to vitamins, minerals, and herbal products was growing, but manufacturers faced uncertainty about labeling, ingredient combinations, and marketing claims. Congress passed DSHEA to create a clear legal category specifically for dietary supplements, balancing consumer choice with public safety.
DSHEA defines a dietary supplement as a product (other than tobacco) intended to supplement the diet and containing one or more dietary ingredients such as vitamins, minerals, amino acids, herbs, or other botanicals. The law applies to products intended for oral intake that are labeled as supplements. This definition is broad enough to encompass most over-the-counter wellness products but excludes conventional foods and pharmaceutical drugs.
How Supplements Differ from Drugs Under DSHEA
The central distinction DSHEA makes is between dietary supplements and drugs. A drug must be proven safe and effective through clinical trials before the FDA approves it for sale. Manufacturers must submit a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) to the FDA, providing rigorous evidence that the product works as claimed and is safe at recommended doses.
Supplements, by contrast, do not require pre-market FDA approval. Manufacturers are responsible for determining that their supplements are safe and that any claims made are truthful and not misleading. The FDA's role is primarily reactive: the agency can investigate complaints, request safety data if concerns arise, and remove unsafe products from the market after they have been distributed. This distinction reflects DSHEA's intent to keep supplements accessible while maintaining a baseline of safety oversight.
The boundary between supplement and drug can blur. If a product makes a claim that explicitly names a disease—such as
Frequently asked questions
What does DSHEA allow manufacturers to claim on supplement labels?
DSHEA allows structure–function claims, which describe how a nutrient affects normal function (e.g., 'supports bone health,' 'promotes cardiovascular function'). Manufacturers cannot claim that a supplement treats, cures, prevents, or mitigates a disease, or that it reduces the risk of a disease. All claims must be truthful, not misleading, and supported by competent scientific evidence. A disclaimer such as 'These statements have not been evaluated by the FDA' is required on supplement labels when structure–function claims are used.
Can the FDA remove a supplement from the market?
Yes. The FDA can take action against a supplement if it is adulterated (contaminated, improperly manufactured, or contains unlisted ingredients) or misbranded (makes false or disease claims, or lacks required labeling information). The FDA can also remove supplements it determines to be unsafe, though the burden of proof is on the agency after marketing—unlike drugs, for which manufacturers must prove safety upfront. If consumers report serious adverse events, the FDA can investigate and pursue removal.
Who is responsible for ensuring a supplement is safe?
Under DSHEA, the manufacturer and distributor are responsible for ensuring their supplements are safe and properly labeled before sale. They must conduct adequate testing, maintain quality control, and be prepared to submit safety data to the FDA if requested. The FDA monitors the market through adverse event reports, laboratory testing, and inspections, but does not pre-screen supplements. This shared responsibility model means consumers and healthcare providers should research brands and report any adverse effects.
What is Current Good Manufacturing Practice (CGMP) for supplements?
CGMP rules, finalized by the FDA in 2007, require supplement manufacturers to maintain quality control standards similar to those for pharmaceuticals. These include proper facility design, employee training, equipment maintenance, testing of raw materials and finished products, and documentation of all manufacturing steps. Compliance with CGMP helps reduce contamination and ensures that supplements contain the identity, purity, and potency claimed on the label.
Can supplements make claims about preventing disease?
No. DSHEA strictly prohibits disease-prevention claims on supplement labels. A supplement cannot claim to 'prevent heart disease,' 'reduce cancer risk,' or 'prevent diabetes.' However, supplements can make structure–function claims such as 'supports heart health' or 'supports immune function,' which describe normal physiological benefit without naming a disease. This distinction is carefully monitored by the FDA and the FTC (Federal Trade Commission).
Has DSHEA been updated since 1994?
DSHEA itself has not been substantially amended, though the FDA has issued clarifications and regulations (such as CGMP rules in 2007 and guidance on new dietary ingredients). The law remains the foundational framework for supplement regulation. Proposals to strengthen oversight or require pre-market notification have been introduced but not enacted into law. Industry and advocacy groups continue to discuss potential updates to address emerging safety and labeling concerns.
